Valion Bio, Inc.
VBIO· Nasdaq
VBIOValion Bio, Inc.
Filed Nov 14, 2022 · 10-Q · 45 days after period end · 0000950170-22-025033
| Metric | Q3 2022 | Q3 2021 |
|---|---|---|
| Revenue | $477.00K | $277.00K |
| Net Income | -$2.58M | -$2.32M |
| EPS Diluted | -$27.00 | -$0.90 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Valion Bio, Inc. · CIK 1787740 · Engraved from SEC EDGAR
ended Sep 30, 2022 · filed Nov 14, 2022 · 45 d after period end
